Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies

J Oncol Pharm Pract. 2024 Oct;30(7):1207-1213. doi: 10.1177/10781552231213883. Epub 2023 Nov 19.

Abstract

Introduction: Cefepime is a fourth-generation cephalosporin and is a workhorse for the empiric treatment of febrile neutropenia (FN). Beta-lactam therapeutic drug monitoring (TDM) has emerged as a dose optimization strategy in patient populations with altered kinetics. Prior literature has demonstrated that patients with FN exhibit augmented renal clearance which may lead to subtherapeutic drug concentrations with standard dosing regimens. The aim of this study was to evaluate pharmacokinetic/pharmacodynamic (PK/PD) target attainment and clinical outcomes in patients with hematologic malignancies and FN who were treated empirically with cefepime.

Methods: This was a prospective, single-center study of adults with hematologic malignancies and FN admitted to the inpatient unit. The primary outcome was PK/PD target attainment (defined as 100% free time greater than minimum inhibitory concentration (100% fT > MIC)). Secondary clinical outcomes were time to defervescence, time to ANC recovery, in-hospital mortality, and cefepime failure.

Results: There were 55 patients in our study. Forty-three (78%) patients achieved the primary outcome of PK/PD target attainment. The mean time to defervescence was similar between those that achieved PK/PD target attainment and those that did not (95% CI -0.75 to 1.25, p = 0.62).

Conclusions: This study showed that standard cefepime dosing in patients with hematologic malignancies and FN does not result in achievement of 100% fT > MIC in all patients. Patients in the group that did not achieve PK/PD target attainment were younger with increased creatinine clearance, indicating that cefepime TDM may be especially beneficial in these patients.

Keywords: Cefepime; neutropenia; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / pharmacokinetics
  • Anti-Bacterial Agents* / therapeutic use
  • Cefepime* / administration & dosage
  • Cefepime* / pharmacokinetics
  • Cefepime* / therapeutic use
  • Cephalosporins / administration & dosage
  • Cephalosporins / pharmacokinetics
  • Cephalosporins / therapeutic use
  • Drug Monitoring* / methods
  • Febrile Neutropenia* / drug therapy
  • Female
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / drug therapy
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome

Substances

  • Cefepime
  • Anti-Bacterial Agents
  • Cephalosporins